VENUS REMEDIES
|
VENUS REMEDIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 76.90 | 33.90 | 21.31 | 19.87 | 30.47 |
| CEPS(Rs) | 96.10 | 50.74 | 41.10 | 44.04 | 55.55 |
| DPS(Rs) | 10.00 | - | - | - | - |
| Book NAV/Share(Rs) | 496.56 | 419.65 | 364.74 | 344.38 | 329.50 |
| Tax Rate(%) | 23.38 | 36.91 | 36.18 | 29.96 | -11.85 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.14 | 10.50 | 9.91 | 10.81 | 10.35 |
| EBIT Margin(%) | 17.44 | 11.01 | 7.44 | 6.85 | 6.15 |
| Pre Tax Margin(%) | 17.43 | 11.00 | 7.42 | 6.83 | 6.07 |
| PAT Margin (%) | 13.36 | 6.94 | 4.74 | 4.78 | 6.79 |
| Cash Profit Margin (%) | 16.69 | 10.39 | 9.13 | 10.60 | 12.37 |
| Performance Ratios | |||||
| ROA(%) | 13.10 | 6.75 | 4.64 | 4.50 | 7.18 |
| ROE(%) | 16.79 | 8.64 | 6.01 | 5.90 | 9.85 |
| ROCE(%) | 21.88 | 13.17 | 8.67 | 7.72 | 7.89 |
| Asset Turnover(x) | 0.98 | 0.97 | 0.98 | 0.94 | 1.06 |
| Sales/Fixed Asset(x) | 1.20 | 1.04 | 0.98 | 0.91 | 0.98 |
| Working Capital/Sales(x) | 3.30 | 2.51 | 2.15 | 2.31 | 3.24 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.83 | 0.96 | 1.02 | 1.09 | 1.02 |
| Receivable days | 51.10 | 53.87 | 47.69 | 37.87 | 21.48 |
| Inventory Days | 54.51 | 62.11 | 73.32 | 80.68 | 74.69 |
| Payable days | 96.77 | 69.91 | 53.52 | 55.69 | 57.31 |
| Valuation Parameters | |||||
| PER(x) | 10.74 | 8.84 | 15.31 | 8.15 | 8.82 |
| PCE(x) | 8.59 | 5.90 | 7.94 | 3.68 | 4.84 |
| Price/Book(x) | 1.66 | 0.71 | 0.89 | 0.47 | 0.82 |
| Yield(%) | 1.21 | - | - | - | - |
| EV/Net Sales(x) | 1.40 | 0.49 | 0.68 | 0.37 | 0.59 |
| EV/Core EBITDA(x) | 6.72 | 3.81 | 5.75 | 2.90 | 5.00 |
| EV/EBIT(x) | 8.00 | 4.48 | 9.15 | 5.37 | 9.54 |
| EV/CE(x) | 1.62 | 0.57 | 0.77 | 0.41 | 0.61 |
| M Cap / Sales | 1.43 | 0.61 | 0.73 | 0.39 | 0.60 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 17.88 | 8.55 | 8.27 | -7.44 | 9.50 |
| Core EBITDA Growth(%) | 89.22 | 18.69 | 1.19 | -0.11 | -4.07 |
| EBIT Growth(%) | 86.66 | 60.70 | 17.58 | 3.14 | -40.09 |
| PAT Growth(%) | 126.83 | 59.05 | 7.25 | -34.77 | -34.07 |
| EPS Growth(%) | 126.83 | 59.05 | 7.25 | -34.77 | -39.12 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | 0.08 | 0.09 | 0.10 |
| Current Ratio(x) | 2.44 | 2.91 | 4.53 | 3.91 | 3.00 |
| Quick Ratio(x) | 1.64 | 2.17 | 2.99 | 2.46 | 1.64 |
| Interest Cover(x) | 3,656.40 | 1,099.26 | 477.45 | 322.44 | 76.69 |
| Total Debt/Mcap(x) | - | - | 0.09 | 0.20 | 0.12 |
Compare Financial Ratios of peers of VENUS REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VENUS REMEDIES | ₹2,041.6 Cr | -1.5% | -12.2% | 200.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -2.6% | 2.4% | 14.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹221,666.0 Cr | 6.5% | 23.3% | 25.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,108.0 Cr | 2.6% | 3% | 33.5% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -1.1% | -0.2% | -7.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,990.9 Cr | 2.6% | -13.3% | -10.7% | Stock Analytics | |
VENUS REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VENUS REMEDIES | -1.5% |
-12.2% |
200.9% |
| SENSEX | 1.2% |
0.4% |
-2.9% |
You may also like the below Video Courses
